Autologous T Cell Isolation & Enrichment Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Developing TAC-T therapies is often constrained by the difficulty of isolating high-purity, functional T cells from limited patient samples without compromising viability. Our Autologous T Cell Isolation & Enrichment Service is specifically designed to overcome this barrier. Utilizing a gentle, column-free magnetic separation system with superparamagnetic beads, our process minimizes cellular stress. This ensures you receive a highly viable and phenotypically precise T cell population, accelerating your therapeutic candidates from research into robust, clinically-ready production.

Introduction

T Cell Antigen Coupler (TAC) T cells represent a promising alternative to conventional CAR-T therapies, as they leverage the complete endogenous T cell receptor (TCR) signaling complex to drive tumor cell killing while minimizing cytokine release and avoiding tonic signaling. The clinical application of cell therapies for solid tumors, however, is hampered by insufficient T cell infiltration, poor persistence, and a suppressive tumor microenvironment. A novel NECTIN-4-redirected TAC-T cell variant, NECTIN-4 TAC28-T, engineered with the intracellular co-stimulatory CD28 domain to enhance its anti-tumor potency.

Fig.1 Efficient development of NECTIN-4 targeted TAC28-T cells featuring CD28 and minimal basal activity. (OA Literature) Fig.1 Generation of tonic signal-free NECTIN-4-specific TAC28-T cells containing CD28.¹

Autologous T Cell Isolation & Enrichment Service at Creative Biolabs

Creative Biolabs supports the seamless transition from fundamental immunology research to personalized therapeutics. We specialize in supplying highly pure and viable T-cell populations, meticulously prepared for advanced downstream modalities including TAC-T, CAR-T, TCR-T, and TIL therapies. Our gentle, patient-specific isolation process is engineered to reduce cellular stress, providing an optimized starting material designed for successful expansion and clinical application.

What We Can Offer

Our service offers tailored, state-of-the-art autologous T cell isolation and enrichment solutions specifically designed to overcome the key bottlenecks in developing next-generation TAC-T cell therapies.

Featured services of autologous T cell isolation & enrichment service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Leukopak or Whole Blood: Fresh or cryopreserved patient-derived apheresis products.
Sample Metadata: Specific target parameters including desired cell subsets and any known donor-specific constraints.

Key Steps:

Workflow of autologous T cell isolation & enrichment service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Purified T Cell Population: Vials of enriched autologous T cells with verified expansion potential.
Comprehensive Analytical Report: Data including purity percentages, viability scores, and fold-expansion projections.

Key Advantages

Tailored Isolation Protocols: Completely customized procedures designed according to your unique target markers, covering rare T-cell subsets and individualized patient profiles.
Enhanced Cellular Viability: Utilization of non-column gentle methods alongside superparamagnetic bead technology to preserve optimal cell health and improve expansion efficiency.
Regulatory-Ready Documentation: Complete, auditable records suitable for IND submissions, with full traceability from cell source through processing, aligned with international quality assurance standards.

FAQs

Q1: Can specific T cell subsets, such as Tregs or memory cells, be isolated?

A1: Yes. Our platform enables precise enrichment of defined T cell subsets, including CD4⁺CD25⁺ regulatory T cells (Tregs), T memory stem cells (Tscm), and other rare or functionally specialized populations. This is achieved through antibody panels tailored to your targets, combined with high-precision magnetic bead separation, ensuring both purity and functional integrity for downstream applications.

Q2: How does your service handle samples with low T cell counts?

A2: We specialize in processing low-input and challenging samples, such as those from heavily pre-treated or lymphopenic patients. Our optimized workflow integrates high-sensitivity tetramer staining and enhanced magnetic enrichment technologies, which maximize the recovery of viable and functional T cells. This approach maintains cell fitness and supports successful expansion, even from limited starting material.

Why Choose Us?

Choose our service for a "cell-first" approach that prioritizes T cell physiological integrity. Our unique column-free platform avoids the shear stress of traditional methods, preventing unintended activation and ensuring high viability and functionality, delivering purity, compliance, and scalability for your clinical-grade therapeutics.

Customer Reviews

"Our work depends on isolating rare, antigen-specific T cells from challenging patient samples. Creative Biolabs delivered exceptional 92% purity within two weeks, turning a major bottleneck into a streamlined process. This efficiency allowed us to advance directly into pilot manufacturing, accelerating our project timeline significantly."

— Dr. Elena Rodriguez, Senior Scientist.

"The high viability and consistency of the isolated CD3⁺ T cells from Creative Biolabs were decisive for our Phase I success. Integrating their platform resulted in zero batch failures, providing the reliability required for clinical manufacturing. Their service has become a cornerstone of our production process."

— Michael Thorne, VP of Manufacturing.

How to contact us?

Looking to enhance your autologous T cell therapy with high purity, viability, and compliance? Contact our senior scientists today for a customized proposal and expert project support. Let's advance your therapeutic pipeline together.

Reference

Wei, Cheng et al. "NECTIN-4-redirected T cell Antigen Coupler T cells bearing CD28 show superior antitumor responses against solid tumors." Frontiers in immunology vol. 15 1456443. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1456443

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.